Epizyme reported $6.06M in Gross Profit on Sales for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Gross Profit On Sales Change
Abbott ABT:US $ 6908M 160M
Amarin AMRN:US $ 72.39M 41.46M
Amgen AMGN:US $ 4677M 451M
Biogen BIIB:US $ 1777.9M 295.8M
Daiichi Sankyo 4568:JP Y 145095M 43967M
Eisai 4523:JP Y 140163M 18587M
Epizyme EPZM:US $ 6.06M 2.37M
Exelixis EXEL:US $ 342.78M 95.45M
Gilead Sciences GILD:US $ 5166M 549M
Glaxosmithkline GSK:US $ 6135M 283M
GlaxoSmithKline GSK:LN 6.14B 283M
Karyopharm Therapeutics KPTI:US $ 46.24M 79.28M
MacroGenics MGNX:US 11.05M 2.15M
Merk MRK:US $ 10567M 873M
Novartis NVS:US $ 9059M 463M
Novartis NOVN:VX 9.06B 463M
Pfizer PFE:US $ 15651M 1516M
Regeneron Pharmaceuticals REGN:US $ 2560.2M 1408.9M
Seattle Genetics SGEN:US $ 338.83M 4.33M
Vertex Pharmaceuticals VRTX:US $ 1851.7M 26.53M